JPRN-UMIN000020144已完成1 期
Phase I/II Study of Irinotecan and Gemcitabine in Pediatric, adolescent and Young Adult Patients with Relapsed or Refractory Solid Tumors - IG chemotherapy for Relapsed Pediatric/AYA Solid Tumor pI/II
Group for "combination chemotherapies for refractory Adolescent and Young Adult solid tumors "0 个研究点目标入组 10 人开始时间: 2015年12月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 1years-old 至 40years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment 2. Active infection requiring systemic medication 3. abnormality in electrocardiogram tested within 28 days, requiring intervention 4. respiratory or heart disorder requiring oxygen supply, except from malignant pleural effusion 5. diarrhea >= Grade2 6. Women during pregnancy or breast-feeding 7. Psychosis 8. Systemic steroids or other immunosuppressants medication 9. Principal investigator determines that the case is Inappropriate to register for this study
研究者
相似试验
已完成
1 期
Phase I/II Trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Ovarian cancer.Patients with platinum-refractory and &#8211resistant ovarian cancer ( including fallopian tube, primary peritoneal cancer)JPRN-UMIN000004449School of Medicine, Chiba University25
已完成
不适用
Phase II Clinical Trial of Gemcitabine and Irinotecan for Unresectable and Recurrent Pancreatic Cancernresectable or Recurrent Pancreatic Cancer (PC)JPRN-UMIN000009963Osaka Medical Center for Cancer and CVD40
招募中
2 期
Phase II randomized trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Mullerian carcinoma (tailored dose vs optimal dose chemotherapy)Patients with platinum refractory and resistant Mullerian carcinoma (ovarian cancer, fallopian tubal, primary peritoneal cancer)JPRN-UMIN000006999School of Medicine, Chiba University64
已完成
1 期
A Phase I/II Study of Amrubicine and Irinotecan in Patients with Advanced Small Cell Lung Cancersmall cell lung cancerJPRN-C000000150West Japan Oncology Group40
已完成
1 期
Phase I Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for EGFR Mutations Non-Small Cell Lung CancerJPRN-UMIN000005873Hamamatsu University School of Medicine, First Department of Surgery1